These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 22683459)

  • 1. Cardiac conduction block at multiple levels caused by arsenic trioxide therapy.
    Kathirgamanathan K; Angaran P; Lazo-Langner A; Gula LJ
    Can J Cardiol; 2013 Jan; 29(1):130.e5-6. PubMed ID: 22683459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monomorphic ventricular tachycardia caused by arsenic trioxide therapy for acute promyelocytic leukaemia.
    Ducas RA; Seftel MD; Ducas J; Seifer C
    J R Coll Physicians Edinb; 2011 Jun; 41(2):117-8. PubMed ID: 21677914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complete atrioventricular block after arsenic trioxide treatment in an acute promyelocytic leukemic patient.
    Huang CH; Chen WJ; Wu CC; Chen YC; Lee YT
    Pacing Clin Electrophysiol; 1999 Jun; 22(6 Pt 1):965-7. PubMed ID: 10392399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperleukocytosis from arsenic trioxide.
    Levy M; Wofford MM; Powell BL; McLean TW
    Pediatr Blood Cancer; 2008 Jun; 50(6):1265-7. PubMed ID: 18300308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-lethal bone marrow necrosis under first-line arsenic trioxide therapy in acute promyelocytic leukaemia.
    Ianotto JC; Tempescul A; Eveillard JR; Charles F; Berthou C
    Acta Haematol; 2010; 123(3):146-7. PubMed ID: 20134156
    [No Abstract]   [Full Text] [Related]  

  • 6. Two cases of monocular visual loss during oral arsenic trioxide therapy of acute promyelocytic leukemia.
    Au WY; Hon C; Yau K; Lai WW; Fong BM; Tam S; Kwong YL
    Am J Hematol; 2009 Oct; 84(10):699. PubMed ID: 19705432
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of arsenic trioxide on QT interval in patients with advanced malignancies.
    Barbey JT; Pezzullo JC; Soignet SL
    J Clin Oncol; 2003 Oct; 21(19):3609-15. PubMed ID: 14512391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Arsenic trioxide: "a successful poison" in patients with acute promyelocytic leukemia].
    Lengfelder E; Schultheis B; Büchner T; Hehlmann R
    Dtsch Med Wochenschr; 2007 Feb; 132(7):330-6. PubMed ID: 17286223
    [No Abstract]   [Full Text] [Related]  

  • 9. Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia.
    Ghavamzadeh A; Alimoghaddam K; Rostami S; Ghaffari SH; Jahani M; Iravani M; Mousavi SA; Bahar B; Jalili M
    J Clin Oncol; 2011 Jul; 29(20):2753-7. PubMed ID: 21646615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing two arsenic trioxide administration methods in APL therapy.
    Zhou J; Meng R; Yang BF
    Chin Med J (Engl); 2004 Sep; 117(9):1411-3. PubMed ID: 15377438
    [No Abstract]   [Full Text] [Related]  

  • 11. Arsenic-based therapy benefits leukemia patients.
    FDA Consum; 2001; 35(1):4. PubMed ID: 11930925
    [No Abstract]   [Full Text] [Related]  

  • 12. Arsenic trioxide: new preparation. Acute promyelocytic leukaemia: encouraging results but persistent doubts.
    Prescrire Int; 2004 Aug; 13(72):135-7. PubMed ID: 15532137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute promyelocytic leukemia complicated by massive intracerebral hemorrhage: safety and efficacy of replacing conventional chemotherapy with arsenic trioxide in an adolescent.
    Müller E; Seidel MG; Lackner H; Dworzak M; Urban C
    Klin Padiatr; 2013 May; 225(3):172-3. PubMed ID: 23625686
    [No Abstract]   [Full Text] [Related]  

  • 14. Arsenic trioxide for the treatment of acute promyelocytic leukemia.
    Lam MS; Ignoffo RJ
    Cancer Pract; 2001; 9(3):155-7. PubMed ID: 11879303
    [No Abstract]   [Full Text] [Related]  

  • 15. Entry of elemental arsenic into the central nervous system in patients with acute promyelocytic leukemia during arsenic trioxide treatment.
    Au WY; Tam S; Kwong YL
    Leuk Res; 2008 Feb; 32(2):357-8. PubMed ID: 17662385
    [No Abstract]   [Full Text] [Related]  

  • 16. Use of arsenic trioxide in a hemodialysis-dependent patient with relapsed acute promyelocytic leukemia.
    Perreault S; Moeller J; Patel K; Eyler R; Pham T; Russell K; Podoltsev N
    J Oncol Pharm Pract; 2016 Aug; 22(4):646-51. PubMed ID: 25972392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arsenic trioxide newly joins treatment strategies for acute promyelocytic leukemia.
    Kuriyama K
    Intern Med; 2001 Dec; 40(12):1165. PubMed ID: 11813833
    [No Abstract]   [Full Text] [Related]  

  • 18. Impairment of heart rate variability control during arsenic trioxide treatment for acute promyelocytic leukemia.
    Takeshita A; Uehara A; Shinjo K; Naito K; Sahara N; Yamazaki K; Katoh H; Kamikawa T; Ohnishi K; Maekawa M; Hayashi H; Ohno R
    Leukemia; 2004 Mar; 18(3):647-8. PubMed ID: 14671633
    [No Abstract]   [Full Text] [Related]  

  • 19. Arsenic-induced pericardial and pleural effusion without acute promyelocytic leukemia differentiation syndrome.
    Ueda K; Nagai S; Miyashita SI; Kaise T; Ichikawa M; Kumano K; Hangaishi A; Nannya Y; Kurokawa M
    Leuk Res; 2010 Jan; 34(1):e25-6. PubMed ID: 19747729
    [No Abstract]   [Full Text] [Related]  

  • 20. Cardiotoxicity in African-American patients treated with arsenic trioxide for acute promyelocytic leukemia.
    Patel SP; Garcia-Manero G; Ferrajoli A; Faderl S; Verstovek S; Kantarjian H; Estey E
    Leuk Res; 2006 Mar; 30(3):362-3. PubMed ID: 16168477
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.